Agile Therapeutics (Agile Therapeutics) Cash-to-Debt : 1.18 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Agile Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Agile Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.18.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Agile Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Agile Therapeutics's Cash-to-Debt or its related term are showing as below:

AGRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.08 Med: 2.91 Max: No Debt
Current: 1.18

During the past 12 years, Agile Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 1.08. And the median was 2.91.

AGRX's Cash-to-Debt is ranked better than
53.2% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs AGRX: 1.18

Agile Therapeutics Cash-to-Debt Historical Data

The historical data trend for Agile Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Agile Therapeutics Cash-to-Debt Chart

Agile Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

200.46

3.30

1.08

2.37

1.18

Agile Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.37	2.00	1.03	1.14	1.18

Competitive Comparison of Agile Therapeutics's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agile Therapeutics's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Agile Therapeutics's Cash-to-Debt falls into.

Agile Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Agile Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.557	/	(2.072	+	0.1)
	=	1.18

Agile Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.557	/	(2.072	+	0.1)
	=	1.18

Agile Therapeutics (OTCPK:AGRX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Agile Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Agile Therapeutics (Agile Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 College Road East, Suite 310, Princeton, NJ, USA, 08540

Website

https://www.agiletherapeutics.com

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.

Executives

Scott M Coiante	officer: Chief Financial Officer	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Josephine Torrente	director	101 POOR FARM ROAD, PRINCETON NY 08540
Sandra Carson	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
John W Hubbard	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Amy Welsh	officer: Chief Commercial Officer	500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540
Alfred Altomari	director, officer: Chief Executive Officer	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Dennis Reilly	officer: Chief Financial Officer	600 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jason Butch	officer: Principal Accounting Officer	101 POOR FARM ROAD, PRINCETON NJ 08540
Paul Korner	officer: Sr. VP & Chief Medical Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abhijeet J Lele	director, See remarks	C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003